Merck's Keytruda-Eisai's Lenvima Combo Make the Cut in Renal Cancer
Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry.
Merck and the partner Eisai presented investigational data from the pivotal Phase III CLEAR study (KEYNOTE-581/Study 307) evaluating Keytruda and Lenvima combination. The results demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) in first-line advanced renal cell carcinoma (RCC) patients...
